FibroBiologics, Inc. FBLG
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.53M | 8.61M | 9.24M | 9.81M | 9.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.73M | 17.19M | 16.65M | 17.77M | 16.09M |
| Operating Income | -16.73M | -17.19M | -16.65M | -17.77M | -16.09M |
| Income Before Tax | -18.14M | -18.68M | -18.65M | -18.50M | -13.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.14 | -18.68 | -18.65 | -18.50 | -13.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.14M | -18.68M | -18.65M | -18.50M | -13.22M |
| EBIT | -16.73M | -17.19M | -16.65M | -17.77M | -16.09M |
| EBITDA | -16.47M | -16.93M | -16.41M | -17.55M | -15.89M |
| EPS Basic | -5.74 | -7.50 | -8.88 | -9.62 | -7.23 |
| Normalized Basic EPS | -3.59 | -4.69 | -5.55 | -6.01 | -4.52 |
| EPS Diluted | -5.74 | -7.50 | -8.88 | -9.62 | -7.23 |
| Normalized Diluted EPS | -3.59 | -4.69 | -5.55 | -6.01 | -4.52 |
| Average Basic Shares Outstanding | 15.21M | 10.87M | 8.93M | 7.63M | 7.15M |
| Average Diluted Shares Outstanding | 15.21M | 10.87M | 8.93M | 7.63M | 7.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |